While Mylan (MYL) has consistently made headlines for controversy over the pricing of its EpiPen, an auto-injector used to treat anaphylaxis and severe food allergies, there's more to the pricing of its competitor than meets the eye. Released today, Kaleo's Auvi-Q will cost insurers 9 times more than the Epipen. In response, Express Scripts (ESRX) , UnitedHealth Group (UNH) and Cigna (CI) will not cover the device.
More from Video
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.
There is a lot of Apple news to chew on Wednesday.